An alternate explanation is that at the higher, 10.0 μg/g, dose, OPG-Fc also inhibits TRAIL [as 10× more OPG is required to inhibit TRAIL versus RANKL (51)], and TRAIL has beneficial effects in the context of T1D (71). This evidence concerns the gene TNFSF11 and type 1 diabetes mellitus.